Novel dalbavancin-PLLA implant coating prevents hematogenous Staphylococcus aureus infection in a minimally invasive mouse tail vein model
- PMID: 36466340
- PMCID: PMC9713003
- DOI: 10.3389/fbioe.2022.1021827
Novel dalbavancin-PLLA implant coating prevents hematogenous Staphylococcus aureus infection in a minimally invasive mouse tail vein model
Abstract
Infective/bacterial endocarditis is a rare but life-threatening disease with a hospital mortality rate of 22.7% and a 1-year mortality rate of 40%. Therefore, continued research efforts to develop efficient anti-infective implant materials are of the utmost importance. Equally important is the development of test systems that allow the performance of new materials to be comprehensively evaluated. In this study, a novel antibacterial coating based on dalbavancin was tested in comparison to rifampicin/minocycline, and the suitability of a recently developed mouse tail vein model for testing the implant coatings was validated. Small polymeric stent grafts coated with a poly-L-lactic acid (PLLA) layer and incorporated antibiotics were colonized with Staphylococcus (S.) aureus before implantation into the tail vein of mice. The main assessment criteria were the hematogenous spread of the bacteria and the local tissue reaction to the contaminated implant. For this purpose, colony-forming units (CFU) in the blood, spleen and kidneys were determined. Tail cross sections were prepared for histological analysis, and plasma cytokine levels and expression values of inflammation-associated genes were examined. Both antibiotic coatings performed excellently, preventing the onset of infection. The present study expands the range of available methods for testing the anti-infectivity of cardiovascular implants, and the spectrum of agents for effective surface coating.
Keywords: antibiotic coating; cardiovascular implants; dalbavancin; hematogenous implant-related infections; in vivo biofilm model; rifampicin/minocycline.
Copyright © 2022 Kloss, Moerke, Woitschach, Wulf, Illner, Schulz, Pauker, Riedel, Grabow, Ince, Reisinger and Sombetzki.
Conflict of interest statement
VP was employed by the company Ceva Animal Health GmbH. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Effect on infection resistance of a local antiseptic and antibiotic coating on osteosynthesis implants: an in vitro and in vivo study.J Orthop Res. 2006 Aug;24(8):1622-40. doi: 10.1002/jor.20193. J Orthop Res. 2006. PMID: 16779814
-
Novel Antibiotic-loaded Point-of-care Implant Coating Inhibits Biofilm.Clin Orthop Relat Res. 2015 Jul;473(7):2270-82. doi: 10.1007/s11999-014-4130-8. Clin Orthop Relat Res. 2015. PMID: 25604874 Free PMC article.
-
Layer-by-layer self-assembly of minocycline-loaded chitosan/alginate multilayer on titanium substrates to inhibit biofilm formation.J Dent. 2014 Nov;42(11):1464-72. doi: 10.1016/j.jdent.2014.06.003. Epub 2014 Jun 12. J Dent. 2014. PMID: 24930872
-
Antibacterial Activity of Ag-Hydroxyapatite Coating Against Hematogenous Infection by Methicillin-Resistant Staphylococcus aureus in the Rat Femur.J Orthop Res. 2019 Dec;37(12):2655-2660. doi: 10.1002/jor.24431. Epub 2019 Aug 20. J Orthop Res. 2019. PMID: 31373384
-
Prophylaxis and treatment of implant-related infections by antibiotic-coated implants: a review.Injury. 2006 May;37 Suppl 2:S105-12. doi: 10.1016/j.injury.2006.04.016. Injury. 2006. PMID: 16651063 Review.
Cited by
-
Native Infective Endocarditis: A State-of-the-Art-Review.Microorganisms. 2024 Jul 19;12(7):1481. doi: 10.3390/microorganisms12071481. Microorganisms. 2024. PMID: 39065249 Free PMC article. Review.
-
Horizontal Gene Transfer of Antibiotic Resistance Genes in Biofilms.Antibiotics (Basel). 2023 Feb 4;12(2):328. doi: 10.3390/antibiotics12020328. Antibiotics (Basel). 2023. PMID: 36830238 Free PMC article. Review.
References
LinkOut - more resources
Full Text Sources